# The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma

> **NCT00674167** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 21 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00674167
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-05
- **Primary completion:** 2015-12
- **Final completion:** 2017-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674167, "The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00674167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*